Skip to main content

Alkermes Value Stock - Dividend - Research Selection

Alkermes

ISIN: IE00B56GVS15 , WKN: A1JKVH

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company\'s marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes. It is also developing Aripiprazole Lauroxil NanoCrystal Dispersion; ALKS 5461 for the treatment of depressive disorder; ALKS 3831 to treat schizophrenia; BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; and ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; development and license agreement with AstraZeneca plc; and license and collaboration agreement with Biogen MA Inc. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar?

2024-06-24
Orchestra BioMed Holdings, Inc. (OBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Centessa Pharmaceuticals (CNTA)

2024-06-21
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Nurix Therapeutics (NRIX) and Verona Pharma (VRNA)

2024-06-20
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

What's Driving Intra-Cellular Therapies Inc's Surprising 15% Stock Rally?

2024-06-18
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

The Analyst Landscape: 7 Takes On Alkermes

2024-06-17
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

TD Cowen Initiates a Buy Rating on Alkermes (ALKS)

2024-06-17
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Alkermes initiated with bullish view at TD Cowen, here's why

2024-06-17
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

IHF: Healthcare Dashboard For June

2024-06-16
iShares U.S. Healthcare Providers ETF has underperformed XLV by 47 bps in annualized return since inception. Find out my thoughts on IHF fund.

Optimistic Buy Rating for Alkermes Based on Promising Narcolepsy Treatment Developments

2024-06-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Alkermes (ALKS) Gets a Buy from Jefferies

2024-06-04
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.